Annovis Bio, Inc.
Price Action
Technical Summary
CONSOLIDATINGAnnovis Bio, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 18), showing significant lag compared to the market leaders. Earnings growth of 17% provides fundamental context to the price action. Investors should exercise caution due to high volatility (103% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.89 | +27.31% | ABOVE |
| 50 SMA | $2.23 | +7.41% | ABOVE |
| 100 SMA | $2.68 | -10.47% | BELOW |
| 150 SMA | $2.72 | -11.91% | BELOW |
| 200 SMA | $2.66 | -9.80% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ANVS in an uptrend right now?
ANVS has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ANVS overbought or oversold?
ANVS's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.
Is ANVS outperforming the market?
ANVS has a Relative Strength (RS) Rating of 18 out of 99. ANVS is currently lagging the broader market.
Where is ANVS in its 52-week range?
ANVS is trading at $2.40, which is 44% of its 52-week high ($5.50) and 24% above its 52-week low ($1.44).
How volatile is ANVS?
ANVS has a Beta of 2.16 and 52-week volatility of 103%. It's more volatile than the S&P 500 - expect bigger swings.